Show overview
The IMID Forum has been publishing since 2015, and across the 11 years since has built a catalogue of 410 episodes. That works out to roughly 130 hours of audio in total. Releases follow a fortnightly cadence.
Episodes typically run ten to twenty minutes — most land between 9 min and 26 min — with run-times ranging widely across the catalogue. None of the episodes are flagged explicit by the publisher. It is catalogued as a EN-language Education show.
The show is actively publishing — the most recent episode landed 1 months ago, with 23 episodes already out so far this year. The busiest year was 2020, with 71 episodes published. Published by The Immune-Mediated Inflammatory Disease Forum.
From the publisher
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Latest Episodes
View all 410 episodesDiscussing RA: Infectious complications of RA treatments
Author Interview: Doctor Chung-Mao Kao, May 2026
Discussing PsA: Personalising treatment targets – understanding clinically meaningful improvement
EULAR 2026 Review Podcast
EULAR 2026 Day 4 Highlights Podcast
EULAR 2026 Day 3 Highlights Podcast
EULAR 2026 Day 2 Highlights Podcast
EULAR 2025 Day 1 Highlights Podcast
Discussing RA: Comparative outcomes with upadacitinib in RA
EULAR 2026 Preview Podcast
Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis
Author Interview: Professor Valentino Paci, April 2026
Discussing RA: Updated EULAR recommendations and next-step strategies after TNF inhibitor failure
Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
Author Interview: Professor Helena Marzo-Ortega, March 2026
Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi prescriptions
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper a paper on the malignancy risk in patients with RA initiating b/tsDMARDS, and the evolution of JAKi prescriptions since 2015 in an international collaboration of rheumatoid arthritis registers.
Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeutic switching drivers
Join Dr Sofia Ramiro and Dr Atul Dheodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the impact of shorter versus longer symptom duration on the efficacy of bimekizumab and the factors associated with therapeutic switching in SpA.
Author Interview: Doctor Carlo Tur, February 2026
Join Professor Peter Nash from the Griffith University in Brisbane, and Doctor Carlo Tur, from the department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University, Erlangen-Nurnberg., as they discuss his recent paper ‘Effects of different B-cell-depleting strategies on the lymphatic tissue’.
Author Interview - Professor Andrew Cope, 2026
Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Andrew Cope from the Centre for Rheumatic Diseases, King’s College London, London, UK, as they discuss his recent paper ‘Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial’.
Discussing RA: Pain outcomes and drug effectiveness of JAK inhibitors in RA and PsA
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review a paper by Taylor et al. where authors report the effects of UPA and ADA on pain in patients with active RA or PsA stratified by inflammatory status, and a paper by Sonomoto et al. which shows the effectiveness of TOF, BAR, UPA and FIL in patients with RA.